HLB Life Science Co., Ltd. cancelled the acquisition of 14% stake in HLB Co., Ltd. from Jinyanggon, Hyuna Lee, Hyunsoo Lee, Alex S. Kim, Yongwoong Kim and Coughing season.
November 04, 2020
Share
HLB Life Science Co., Ltd. (KOSDAQ:A067630) agreed to acquire 14% stake in HLB Co., Ltd. from Jinyanggon, Hyuna Lee, Hyunsoo Lee, Alex S. Kim, Yongwoong Kim and Coughing season on November 5, 2019.
HLB Life Science Co., Ltd. (KOSDAQ:A067630) cancelled the acquisition of 14% stake in HLB Co., Ltd. from Jinyanggon, Hyuna Lee, Hyunsoo Lee, Alex S. Kim, Yongwoong Kim and Coughing season on November 5, 2020.
HLB Life Science Co., Ltd. is a Korea-based company mainly engaged in the sale of pharmaceuticals. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. It is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
HLB Life Science Co., Ltd. cancelled the acquisition of 14% stake in HLB Co., Ltd. from Jinyanggon, Hyuna Lee, Hyunsoo Lee, Alex S. Kim, Yongwoong Kim and Coughing season.